Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Issue 1 (9th November 2018)
- Record Type:
- Journal Article
- Title:
- Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Issue 1 (9th November 2018)
- Main Title:
- Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
- Authors:
- Kirsebom, Bjørn‐Eivind
Nordengen, Kaja
Selnes, Per
Waterloo, Knut
Torsetnes, Silje Bøen
Gísladóttir, Berglind
Brix, Britta
Vanmechelen, Eugeen
Bråthen, Geir
Hessen, Erik
Aarsland, Dag
Fladby, Tormod - Abstract:
- Abstract: Introduction: The cerebrospinal fluid neurogranin (Ng)/β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta‐amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer's disease. Methods: We compared Ng/BACE1 levels between cases with subjective cognitive decline (n = 18) and mild cognitive impairment (n = 20) both with amyloid plaques and healthy controls ( APOE ‐ε4+, n = 16; APOE ‐ε4‐, n = 20). We performed regression analyses between cerebrospinal fluid levels, baseline hippocampal and amygdala volumes, and pertinent cognitive measures (memory, attention, Mini Mental State Examination [MMSE]) at baseline and after 2 years. Results: Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls. Higher Ng/BACE1 ratio was associated with lower hippocampal and amygdala volumes; lower baseline memory functions, attention, and MMSE; and significant decline in MMSE and memory function at 2‐year follow‐up. Discussion: High Ng/BACE1 ratio predicts cognitive decline also in preclinical cases with amyloid plaques. Highlights: CSF Ng/BACE1 may confer synapse loss tied to β‐amyloid disease mechanism. CSF Ng/BACE1 is increased already in preclinical cases with amyloid plaques High CSF Ng/BACE1 is the only biomarker related to lower baseline memory function. High CSF Ng is the onlyAbstract: Introduction: The cerebrospinal fluid neurogranin (Ng)/β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta‐amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer's disease. Methods: We compared Ng/BACE1 levels between cases with subjective cognitive decline (n = 18) and mild cognitive impairment (n = 20) both with amyloid plaques and healthy controls ( APOE ‐ε4+, n = 16; APOE ‐ε4‐, n = 20). We performed regression analyses between cerebrospinal fluid levels, baseline hippocampal and amygdala volumes, and pertinent cognitive measures (memory, attention, Mini Mental State Examination [MMSE]) at baseline and after 2 years. Results: Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls. Higher Ng/BACE1 ratio was associated with lower hippocampal and amygdala volumes; lower baseline memory functions, attention, and MMSE; and significant decline in MMSE and memory function at 2‐year follow‐up. Discussion: High Ng/BACE1 ratio predicts cognitive decline also in preclinical cases with amyloid plaques. Highlights: CSF Ng/BACE1 may confer synapse loss tied to β‐amyloid disease mechanism. CSF Ng/BACE1 is increased already in preclinical cases with amyloid plaques High CSF Ng/BACE1 is the only biomarker related to lower baseline memory function. High CSF Ng is the only biomarker related to reduced baseline hippocampal volume. High CSF Ng predicts decline in verbal memory function at 2‐year follow‐up. … (more)
- Is Part Of:
- Alzheimer's & dementia. Volume 4:Issue 1(2018)
- Journal:
- Alzheimer's & dementia
- Issue:
- Volume 4:Issue 1(2018)
- Issue Display:
- Volume 4, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 4
- Issue:
- 1
- Issue Sort Value:
- 2018-0004-0001-0000
- Page Start:
- 617
- Page End:
- 627
- Publication Date:
- 2018-11-09
- Subjects:
- Alzheimer's disease -- MCI (mild cognitive impairment) -- SCD (subjective cognitive decline) -- MRI -- Memory -- Cognition -- Synaptic loss -- Cerebrospinal fluid (CSF) -- CSF neurogranin -- CSF BACE1
Dementia -- Periodicals
Dementia -- Treatment -- Periodicals
Alzheimer's disease -- Treatment -- Periodicals
Alzheimer's disease -- Periodicals
616.831 - Journal URLs:
- https://alz-journals.onlinelibrary.wiley.com/loi/23528737 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.trci.2018.10.003 ↗
- Languages:
- English
- ISSNs:
- 2352-8737
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13321.xml